SinoFresh Healthcare Announces the Acquisition of SRS International, Inc.
December 07 2010 - 10:21AM
SinoFresh® HealthCare, Inc., (Pink Sheets:SFSH) is pleased to
announce that it has acquired SRS International,
Inc.(www.srsinternational.com), a leading consulting and regulatory
company specializing in research and development, compliance and
other regulatory matters. The acquisition of SRS International now
forms the cornerstone of the Research and Development division of
SinoFresh HealthCare, Inc.
SRS International Corporation as a wholly owned operating
subsidiary of SinoFresh HealthCare, Inc. will interface both
domestically and globally to efficiently introduce and support
SinoFresh products entering the marketplace. Extensive
experience in Asia as well as the Western world makes SRS
International Corporation the perfect acquisition to support the
development and introduction of SinoFresh HealthCare, Inc. product
lines in both the national and international markets.
John Todhunter, Principal of SRS International, has a
distinguished record of representing companies before the Food and
Drug Administration and the Environmental Protection Agency, as
well as designing and conducting clinical studies. Todhunter is a
former Presidential Appointee, having been appointed to the EPA by
President Ronald Reagan.
SinoFresh CEO David R. Olund comments, "The acquisition of SRS
International and the addition of John Todhunter to our team are
significant events and signal a vote of confidence in the future of
SinoFresh HealthCare, Inc., by SRS International, a leading company
in the pharmaceutical research and development and clinical studies
field. The DSRS International team immediately brings us regulatory
and product development expertise at a level of competence and
experience that could not easily be duplicated by an emerging
growth-oriented company. Overall, we are truly fortunate to have a
world-class team and John Todhunter forming our R&D
division."
SinoFresh HealthCare, Inc. is a publicly traded company (Pink
Sheets:SFSH) based in Venice, Florida, that manufactures and
distributes nasal, oral and topical antiseptic germ-killing
products. SinoFresh products are marketed and distributed globally
through a network of strategic wholesale and retail partners.
SinoFresh HealthCare, Inc's, premier product, SinoFresh Antiseptic
Homeopathic Nasal spray, has in laboratory tests shown effective
antiseptic capability against a variety of pathogens such as MRSA,
E-Coli, H1N1 and a broad range of other viruses, molds, fungi and
bacteria.
For more information please contact our Investor Relations
department at 941.375.8174 option 8
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. Our
forward-looking statements express our current expectations or
forecasts of possible future results or events, including
projections of future performance, statements of management's plans
and objectives, future contracts, and forecasts of trends and other
matters. Forward-looking statements speak only as of the date of
this filing, and we undertake no obligation to update or revise
such statements to reflect new circumstances or unanticipated
events as they occur. You can identify these statements by the fact
that they do not relate strictly to historic or current facts and
often use words such as "anticipate", "estimate", "expect",
"believe", "will likely result", "outlook", "project" and other
words and expressions of similar meaning. No assurance can be given
that the results in any forward-looking statements will be achieved
and actual results could be affected by one or more factors, which
could cause them to differ materially. For these statements, we
claim the protection of the safe harbor for forward-looking
statements contained in the Private Securities Litigation Reform
Act.
CONTACT: Sinofresh Healthcare Inc.
Investor Relations
941.375.8174 option 8